Mycobacterium Infections Treatment Market- By Bacteria Type , by Drugs , By Distribution Channel , By End-user , By Geography - Global Opportunity Analysis & Industry Forecast, 2024 - 2030

Mycobacterium Infections Treatment Market Overview

The Mycobacterium Infections Treatment Market Size is forecast to reach $ 23790 Million by 2030, at a CAGR of 5.60% during forecast period 2024-2030. Mycobacterium is a genus of Actinomycetota. Around 190 species are recognized under the genus class. The genus class includes pathogens known to cause serious diseases in mammals such as tuberculosis, leprosy and others. Moreover, mycobacterium is acid-fast and cannot be stained under the gram stain procedure. The growing medicinal class pertinent to treating mycobacterium has aided the overall market structure. Some of the commonly used medicines include, but are not limited to, clarithromycin, azithromycin, rifampin, rifabutin, ethambutol, streptomycin, amikacin and others. Oral antibiotics are often revered as the first line of therapy for non-tuberculosis infections. Lastly, the growing population base susceptible to the bacterial class and the rising research and development activities boost the Mycobacterium Infection Treatment Industry outlook during the forecast period of 2025-2031.

Mycobacterium Infections Treatment Market Report Coverage

The report: “Mycobacterium Infections Treatment Market Forecast (2025-2031)" by IndustryARC, covers an in-depth analysis of the following segments in the Mycobacterium Infections Treatment Market.

Key Takeaways

• Geographically, North America held a dominant market share in 2021. It is due to the presence of advanced medical infrastructure that is supported by both private and public entities. However, Asia-Pacific is expected to offer lucrative growth opportunities over the forecast period of 2022-2027, due to the presence of key generic players and a growing base for medical infrastructure.
• The substantial presence of the geriatric population and increased research and development activities for diagnosis and treatment have aided market growth. However, the increased prevalence of antibiotic-resistant drugs has impeded market growth.
• A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Mycobacterium Infections Treatment Market.

Mycobacterium Infections Treatment Market - Market Share (%) by region, 2021

For More Details on This Report - Request for Sample

Mycobacterium Infections Treatment Market Segment Analysis - by Indication

The Mycobacterium Infections Treatment Market based on indication can be further segmented into M. Tuberculosis, M. Leprae, Non-tuberculosis Mycobacteria and Others. M. Tuberculosis held a dominant market size in 2021. It is due to the vast prevalence of the condition and a significant amount of fiscal budgets and regulations aligned by the WHO. As per WHO, around 260,000 TB cases were reported from the EU in 2019, curating a significant fiscal impact. Some of the effective medicines for TB as prescribed by NHS are isoniazid and rifampicin, pyrazinamide and ethambutol. However, the Non-tuberculous Mycobacteria segment is estimated to be the fastest-growing one, with a CAGR of 6.6% over the forecast period of 2022-2027. NTM are opportunistic pathogens, placing some groups at increased risk, including those with underlying lung disease or depressed immune systems. An important reason for the growth of the following condition is an expanding tropic due to climate change which would proliferate the infections pertinent to NTM.

Mycobacterium Infections Treatment Market Segment Analysis - by Distribution Channel

The Mycobacterium Infection Treatment Market based on Distribution Channels can be further segmented into Hospital Pharmacies, Online Pharmacies and Retail Pharmacies. Hospital Pharmacies held a dominant market share in 2021. As per NCBI, TB cases admitted to a hospital range between 50%-100%, while multi-drug resistant TB patients range between 85-100% globally. However, the Retail Pharmacies segment is estimated to be the fastest-growing segment, with a CAGR of 6.5% over the forecast period of 2022-2027. A growing number of mycobacterial infections are asymptomatic, specifically for NTM. Thus, basic antibiotic medicines from secondary clinics shall aid the market growth in the period. As per PCM 2020, between 2010-19, the number of independent pharmacies grew by nearly 13% in the U.S.

Mycobacterium Infections Treatment Market Segment Analysis - by Geography

The Mycobacterium Infection Treatment Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America held a dominant market share of 38% in 2021. It is because of a robust medical infrastructure supported by both public and private infrastructure. Moreover, the U.S. has an extensive medical insurance coverage policy that aids in the overall treatment of people in the market. As per Commonwealth Fund 2020, nearly 92% of the population has had healthcare coverage. However, Asia-Pacific is estimated to be the fastest-growing, with a CAGR over the forecast period of 2022-2027. It is owing to a growing disease-afflicted population in the region, largely supplemented by growing healthcare infrastructure in countries like India and China.

Mycobacterium Infections Treatment Market Drivers

The Strong Presence of the Geriatric Population along with the Increased Prevalence of Tuberculosis in Various Regions:

Tuberculosis remains a rampant infectious disease of global importance. The epidemiology of the disease varies as per the region. The geriatric population in developed countries, such as the United States, represents a large reservoir of tuberculosis infection across all ethnic and sex subsets. The World Health Organization (WHO) estimates that there are about 10.4 million new cases and 1.8 million deaths from Tuberculosis each year globally. Furthermore, the number of nursing home residents has increased, which has resulted in a 2-3-fold increase in tuberculosis in the geriatric community.

Increased Research Activities Pertinent to Diagnosis and Treatment:

Updated guidelines and a new operational handbook on the tests for the diagnosis of TB have been released by the WHO on September 2022. They highlight the importance of ready surveillance and treatment of those afflicted with the condition. The updated policy includes, for the first time, recommendations on a new class of Mycobacterium tuberculosis antigen-based skin tests (TBSTs) and consolidates all currently existing recommendations for the diagnosis of TB infection, including the traditional tuberculin skin test (TST) and interferon-gamma release assays (IGRAs). As per ASM Journal, QFT- Plus Test demonstrated nearly 80% accuracy in the final TB diagnosis.

Mycobacterium Infections Treatment Market Challenges

The Growing Cases of Antibiotic Resistance along with Delayed Diagnosis of Symptoms:

Drug resistance amongst the population is growing at a rampant pace. As per CDC 2021, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year. Subsequently, drug-resistant TB occurs when bacteria become resistant to the drugs used to treat TB. Additionally, the spread of drug-susceptible TB can spread from person to person. Lastly, tuberculosis is often confused with age-related illnesses in the geriatric population. Owing to a weakened immune system in the majority of the senior population, TB cases are often neglected as simple cough and cold and diagnosis happens only if the prognosis stage has exceeded the designated timelines for medicines. This impedes the market growth.

Mycobacterium Infections Treatment Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Mycobacterium Infections Treatment Industry. The top 10 companies in the Mycobacterium Infections Treatment Market are:

1. Insmed Incorporated
2. Red Hill Biopharma
3. Novoteris
4. Savara Inc.
5. Beyond Air
6. Sanofi S.A.
7. Novartis AG
8. Endo Pharmaceuticals
9.  CMP Pharma
10. Johnson and Johnson

Recent Developments

• In October 2022, Microbion Corporation announced the positive effects of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. Moreover, pravibismane can disrupt bacterial bioenergetics and protein synthesis.

• In October 2022, AN2 Therapeutics Inc exacerbated the utility of epetraborole as the potential medicine to offer benefits to patients suffering from NTM Lung Diseases. The Phase-1 Trial in Japan has consolidated the company’s position for future trials.

• In September 2022, the FDA approved Oxford Immunotec’s T-Cell Select reagent kit, which would automate the workflow of the T-SPOT.TB test. This test is a globally regulated ELISPOT IGRA that detects latent tuberculosis (TB) infection, for in-vitro diagnostic (IVD) in certified laboratories.

For more Lifesciences and Healthcare Market reports, please click here